MedTrace Logo

Caffeine Citrate Use and Electronic Activity of the Diaphragm (EDI) Changes

NCT05393817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2023-11-28

No results posted yet for this study

Summary

Caffeine citrate, the first-line agent for apnea of prematurity, enhances diaphragmatic activity. EDI values of neurally adjusted ventilatory assist (NAVA) modes can be used to quantify the diaphragmatic activity triggered by electrical impulse from the respiratory center. This study aims to evaluate the EDI changes following caffeine citrate administration and cessation in preterm infants, and whether such changes are affected by different doses used variably in clinical settings.

Conditions

  • Preterm
  • Apnea of Prematurity
  • Caffeine

Interventions

DRUG

caffeine citrate

caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Sook Kyung Yum, MD, PhD · The Catholic University of Korea

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-08
Primary Completion
2023-10-18
Completion
2023-10-18

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393817 on ClinicalTrials.gov